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This study was performed to assess the efficacy and safety of preoperative chemoradiation consisting of carboplatin and paclitaxel and
concurrent radiotherapy for patients with resectable (T2-3N0-1M0) oesophageal cancer. Treatment consisted of paclitaxel
50mgm
 2 and carboplatin AUC¼2 on days 1, 8, 15, 22 and 29 and concurrent radiotherapy (41.4Gy in 23 fractions, 5 days per
week), followed by oesophagectomy. All 54 entered patients completed the chemoradiation without delay or dose-reduction. Grade
3–4 toxicities were: neutropaenia 15%, thrombocytopaenia 2%, and oesophagitis 7.5%. After completion of the chemoradiotherapy
63% had a major endoscopical response. Fifty-two patients (96%) underwent a resection. The postoperative mortality rate was 7.7%.
All patients had an R0-resection. The pathological complete response rate was 25%, and an additional 36.5% had less than 10% vital
residual tumour cells. At a median follow-up of 23.2 months, the median survival time has not yet been reached. The probability of
disease-free survival after 30 months was 60%. In conclusion, weekly neoadjuvant paclitaxel and carboplatin with concurrent
radiotherapy is a very tolerable regimen and can be given on an outpatient basis. It achieves considerable down staging and a
subsequent 100% radical resection rate in this series. A phase III trial with this regimen is now ongoing.
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The prognosis of oesophageal cancer is poor in symptomatic
patients, for example, those with dysphagia. At the time of first
diagnosis, almost half of such patients already have metastatic
disease; the other half usually has locally advanced disease (T3N0
or T3N1). Furthermore, although surgical resection is still the first
choice of treatment for fit patients with resectable disease, most of
these patients have a poor outcome. This is reflected by a 5-year
survival rate of approximately 20% (Hulscher et al, 2001). Despite
the routine use of staging procedures such as computed
tomography (CT), magnetic resolution imaging (MRI) and
endoscopic ultrasound (EUS), many oesophageal tumours are
incompletely resected (van Meerten and van der Gaast, 2005). In a
number of large randomised studies, the percentage of incomplete
resections varied between 25 and 46% (Kelsen et al, 1998; Hulscher
et al, 2002; MRC, 2002). Hulscher et al found an incomplete
resection rate of 25% in extended transthoracic surgery vs 29% in
limited transhiatal resection for adenocarcinoma of the oeso-
phagus. In the study performed by the Medical Research Counsel,
resection was microscopically complete (R0) in 60% when surgery
was preceded by chemotherapy, and 54% in the surgery alone
group. Kelsen et al found incomplete resections in 14% of the
patients when surgery was preceded by chemotherapy vs 30% for
surgery alone.
Preoperative chemoradiotherapy may induce considerable
tumour shrinkage and thereby increase the number of radical
resections. In this setting, concurrent chemoradiotherapy with 5-
fluorouracil (5-FU) and cisplatin is one of the most commonly
used regimens. Unfortunately, the impact of preoperative chemo-
radiotherapy with 5-FU and cisplatin on survival is uncertain. An
improved 3-year survival was shown in three meta-analyses of
randomised controlled trials comparing neoadjuvant chemora-
diotherapy and surgery to surgery alone (Kaklamanos et al, 2003;
Urschel and Vasan, 2003; Fiorica et al, 2004), but if the study by
Walsh et al (1996) is excluded, this benefit is lost. Furthermore,
chemoradiotherapy with 5-FU and cisplatin can induce severe
toxicity and most patients have to be hospitalised for this
treatment. Thus, the best regimen of preoperative chemoradiation
has not yet been established.
Recently, studies with radiotherapy combined with paclitaxel
with or without cisplatin or carboplatin have shown promising
results in other tumour types. Paclitaxel is a microtubule-
stabilising agent that blocks the cell cycle in the G2 and M phase,
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sthe most radiosensitive phase. The radioenhancing effects of
paclitaxel have been demonstrated in vitro in a human leukaemic
cell line and in cell lines of squamous cell carcinoma and
astrocytoma (Tishler et al, 1992; Choy et al, 1993; Leonard et al,
1996). Besides its radiosensitising effect, it also enhances the result
of radiotherapy by increasing apoptosis and tumour reoxygena-
tion. A weekly schedule permits an increase in dose-intensity and
can provide continuous radiosensitizing plasma drug levels.
The combination of paclitaxel and carboplatin with concurrent
radiotherapy has been tested in patients with advanced non-small-
cell lung cancer. In five phase II studies, the combination of
paclitaxel and carboplatin was given weekly with concurrent
radiotherapy, followed by two or four 21-day cycles of consolida-
tion chemotherapy (Choy et al, 1998, 2000; Lau et al, 2001;
Ratanatharathorn et al, 2001; Kaplan et al, 2004). The overall
response rate varied from 71 to 79%. The major toxicity was
oesophagitis. In 10–46% of the patients a grade 3 or 4 oesophagitis
was found. Treatment with paclitaxel and carboplatin and
concurrent radiotherapy can be given on an outpatient basis,
which is advantageous. Furthermore, this regimen is probably less
toxic than cisplatin-based therapy.
On the basis of these considerations, we initiated a phase II
study to determine the response rate and toxicity of a preoperative
chemoradiotherapy regimen consisting of carboplatin and pacli-
taxel with concurrent radiotherapy in patients with a potentially
resectable carcinoma of the oesophagus.
METHODS
Eligibility criteria
Patients with histologically proven squamous cell carcinoma,
adenocarcinoma, or undifferentiated carcinoma of the oesophagus
with the upper border at least 3cm below the upper oesophageal
sphincter were included. Disease was limited to T1N1 or T2-3N0-
1M0 tumours. Tumours extending below the gastro-oesophageal
(GE) junction into the proximal stomach were also eligible, provided
that the bulk of the tumour was located in the oesophagus. The
longitudinal tumour length had to be p8cm and the radial tumour
length p5cm. Patients were required to be aged 18–75 years and to
have an Eastern Cooperative Oncology Group (ECOG) performance
status of p2. Other criteria included adequate haematological,
renal, hepatic and pulmonary functions as defined by: a granulocyte
count of at least 1500mm
 3 and a platelet count 100000mm
 3;a
serum creatinine level o120mmoll
 1 and a bilirubin level p1.5 
upper normal limit; and a forced expiratory volume in one second
(FEV1) of at least 1.2l. The Medical Ethics Committee of Erasmus
University Medical Centre approved the study. Written informed
consent was required. No previous chemotherapy and radiotherapy
or a past or current history of malignancy other than entry
diagnosis was allowed, except for non-melanomatous skin cancer,
curatively treated carcinoma in situ of the cervix, or a ‘cured’
malignancy more than 5 years before enrolment. Patients were not
eligible if they had lost more than 10% of their body weight or had
an inadequate caloric- and/or fluid intake.
Staging
Pretreatment evaluation included a detailed history taking, a
physical examination and a routine complete blood work-up. All
patients underwent a baseline upper gastrointestinal (GI) endo-
scopy and EUS, and a CT of the chest and the upper abdomen, plus
ultrasonography of the neck and pulmonary function tests.
Treatment
Chemotherapy Paclitaxel 50mgm
 2 and Carboplatin targeted at
an AUC of 2 were administered on days 1, 8, 15, 22 and 29. All
patients received dexamethasone 10mg, clemastine 2mg and
ranitidine 50mg, administered intravenously 30min before
paclitaxel infusion. Paclitaxel was given as a 1-h infusion diluted
in 500ml of sterile and isotonic sodium chloride solution (saline).
After the completion of the paclitaxel infusion, 100ml of saline was
infused over 30min followed by an infusion of 8mg ondansetron
or its equivalent diluted in 100ml of saline given over 30min.
Hereafter, the total calculated dose of carboplatin diluted in 500ml
of 5% dextrose solution was administered over 1-h. Dose
modifications were made for toxicity, using the National Cancer
Institute – Common Toxicity Criteria (NCI-CTC version 2).
Radiotherapy All patients were irradiated by external beam
radiation, using a 3-D conformal radiation technique. The gross
tumour volume (GTV) was defined by the primary tumour and any
enlarged regional lymph nodes, and was drawn on each relevant
CT slice. The planning target volume (PTV) provided a 1.5cm
radial margin and a proximal and distal margin of 4cm around the
GTV. If the tumour extended into the stomach, a distal margin of
3cm was chosen. Before the start of the irradiation, a planning CT
scan was made from the cricoid to L1 vertebra with a slice
thickness of p5mm, with the patient in treatment position.
Beams-eye-view (BEV) was used to ensure optimal target volume
coverage and optimal normal tissue sparing. The prescription dose
was specified at the ICRU 50/62 reference point, which was the
isocenter for most patients. The daily prescription dose was 1.8Gy
at the ICRU reference point and the 95% isodose had to encompass
the entire planning target volume (PTV). The maximum to the
PTV was not allowed to exceed the prescription dose by 47%
(ICRU 50/62) guidelines. Tissue density inhomogeneity correction
was used. Portal images were obtained during the first fraction of
all fields. A total dose of 41.4Gy was given in 23 fractions of 1.8Gy,
with 5 fractions per week starting on the first day of the first cycle
of chemotherapy.
Surgery Surgery was planned within 6 weeks after the completion
of the chemoradiation. For carcinomas located distally of the
tracheal bifurcation, a transhiatal oesophageal resection was
favoured. For carcinomas located proximally to the tracheal
bifurcation, a transthoracic oesophageal resection was performed.
In both techniques, a wide local excision including the N1 lymph
nodes was carried out, including a standard resection of the lymph
nodes around left gastric artery. The continuity of the digestive
tract was restored by means of a gastric tube reconstruction with
an anastomosis in the neck.
Pathological analysis
The resection specimen was evaluated using a standard protocol,
providing information on margins, tumour type, extension of the
tumour, and lymph nodes. The sixth edition of the International
Union Against Cancer (UICC) was used for TNM-classification,
tumour grade, and stage grouping (UICC, 2002). When no tumour
tissue could be seen, lesions such as an ulcer or an irregular area
covered by mucosa were embedded in total together with
surrounding areas in order to adequately judge the presence of
residual tumour and therapy effects. The grading of the therapy
response was performed as described by Junker et al (1997). The
degree of histomorphological regression, that is, the effect of
chemoradiation, was classified into four categories: grade I: more
than 50% vital residual tumour cells; grade II: 10–50% vital
residual tumour; grade III: less than 10% vital residual tumour
cells; grade IV: complete tumour regression, no evidence of vital
tumour cells.
A two-field lymph node dissection was carried out containing
regional (mediastinal, oesophageal) and distant sites (coeliac
region). The resection margins, especially the circumferential
margin, were evaluated with a 1mm cutoff point for vital tumour,
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simplying that the tumour-free margin is 41mm. If vital tumour
was present at p1mm from the surgical resection margin it was
considered positive.
Restaging and follow-up
Upper GI endoscopy and CT of the chest and upper abdomen were
repeated after the completion of the chemoradiation and ahead of
the planned operation. Pulmonary function tests were repeated 6
and 12 months after therapy. Follow-up visits were performed
every 3 months during the first 2 years and every 6 months
thereafter to document late toxic effects, and, if applicable, disease
relapse or progression, and death.
Statistical analysis
As the statistical design was intended to allow us to detect a
response percentage of at least 40%, it was calculated that 50
patients were needed. The pathological response to chemoradia-
tion was defined as mentioned above. The response to chemo-
radiotherapy evaluated by endoscopy was classified as either no
response, less than 50% response, more than 50% response, or
complete response. These broad classifications were used in an
attempt to reduce inter-observer variation (Brown et al, 2004).
Tumour response evaluated by radiology was assessed according
to the response evaluation criteria in solid tumours (RECIST)
(Therasse et al, 2000).
Survival time was calculated as the duration from the day of
start of chemoradiotherapy to death or the last follow-up, and
recurrence-free interval was calculated from the day of surgery to
the day of diagnosis of recurrence. Overall and disease-free
survivals were estimated using the Kaplan–Meier method. Median
survival time was obtained from the time corresponding to 50%
survival based on the Kaplan–Meier survival curve.
RESULTS
Patient characteristics
Fifty-four eligible patients were enrolled between February 2001
and January 2004. Written informed consent was obtained from all
patients. Characteristics of these 54 patients are summarised in
Table 1. Of all patients, 91% were male and 76% had an
adenocarcinoma. Of these 41 adenocarcinomas, 23 were located
at the gastro-oesophageal junction and 18 in the distal oesophagus.
The patient with 12% weight loss was accepted for chemo-
radiotherapy, because the weight loss was partly due to de novo
diagnosed diabetes mellitus.
Toxicity of and adherence to chemoradiotherapy
Fifty-three patients (98%) completed the preoperative treatment.
One patient died at home after the second course of chemotherapy,
probably due to a cardiac arrest. All other patients completed the
neoadjuvant chemoradiotherapy as scheduled, without treatment
delay or dose reduction. The 1.5cm radial radiation margin was
achieved in all patients; there were no compromises. The V20 was
obtained in all patients and never exceeded 30% of the total lung
volume. The acute toxicities due to the chemoradiation were
usually mild. Haematological toxicity is listed in Table 2. Grade 3
or 4 toxicity consisted of leucopaenia in 13 patients (23.5%),
neutropaenia in 8 patients (15.1%), and thrombocytopenia in 1
patient (1.9%). Two patients required a blood transfusion for
anaemia (3.8%). Infectious complications were rare, only one
patient was treated for pneumonia due to aspiration, no
neutropenia was found. Three other patients also developed fever,
but no infectious focus was found (see below). Relevant non-
haematological toxicity (Table 3) consisted mainly of oesophagitis
and dysphagia. Four patients (7.5%) developed grade 3 oeso-
phagitis. Dysphagia improved during chemoradiation in 17 of 35
patients (48.6%), three of whom had initial nutritional support,
because of grade 3 dysphagia, which could be discontinued.
Dysphagia worsened in nine patients (17%), three of whom
required nutritional support because of grade 3 dysphagia. In
three patients needing nutritional support before starting
Table 1 Patient characteristics
Characteristics No. (%)
Total no. of patients 54
Sex
Male 49 (91)
Female 5 (9)
Age (years)
Median 59
Range 40–75
Performance status (ECOG)
0 35 (65)
1 18 (33)
Unknown 1 (2)
Weight loss (%)
a
Median 2
Range 0–12
Histology
Adenocarcinoma 41 (76)
Squamous cell carcinoma 12 (22)
Large cell carcinoma 1 (2)
Barrett’s oesophagus
b
Yes 19 (46)
No 17 (42)
Uncertain 5 (12)
Stage (EUS)
T2N0 5 (9)
T2N1 2 (4)
T3N0 18 (33)
T3N1 21 (39)
No pass 8 (15)
Primary site
Thoracic oesophagus 5 (9)
Lower oesophagus 49 (91)
aCalculated from the data of 52 patients.
bCalculated in 41 patients with
adenocarcinoma. Yes¼Barrett’s oesophagus identified by upper endoscopy and
confirmed by histopathologic examination. No¼No Barrett’s oesophagus identified
by upper endoscopy or by histopathologic examination. Uncertain¼Barrett’s
oesophagus identified by upper endoscopy or by histopathologic examination.
EUS, Endoscopic ultrasound.
Table 2 Haematological toxicities
Grade
01234
(%) No. (%) No. (%) No. (%) No. (%) No. (%)
Anaemia 7 (13.2) 42 (79.2) 4 (7.5) — —
Leucopaenia 4 (7.5) 11 (20.8) 25 (47.2) 12 (22.6) 1 (1.9)
Neutropaenia 17 (32.1) 19 (35.8) 9 (17) 8 (15.1) —
Thrombocytopaenia 30 (56.6) 19 (35.8) 3 (5.7) 1 (1.9) —
Data from 53 evaluable patients.
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schemoradiation the support could not be discontinued during the
chemoradiation. Sensory neuropathy was seen in only five patients
(9.4%), and in three patients it resolved after completion of the
chemoradiotherapy. Seven patients (13.2%) were hospitalised. Five
of them were briefly hospitalized for placing a nasogastric tube for
nutritional support, because of grade 3 oesophagitis or dysphagia.
One also had a pulmonary embolism and fever with grade 3
neutropaenia, one was also treated for pneumonia due to
aspiration, and one patient also had fever with grade 3
neutropenia. One patient was hospitalised because of rectal
bleeding. Colonoscopy revealed a non-malignant polyp, which
was removed. One patient was hospitalised because of vomiting
and fever with grade 2 neutropaenia.
Response to chemoradiotherapy
Evaluation with upper GI endoscopy and CT was done after a
mean of 10 days following the last radiotherapy session. Response
evaluation with endoscopy showed a complete response in 10
patients (18.9%), a major response in 23 patients (43.4%), a minor
response in 11 patients (20.8%), and no response in 1 patient
(1.9%). In five patients response evaluation by endoscopy was not
possible (in one patient there was ‘no pass’, in four patients the
baseline endoscopy was performed in another hospital) and in
three patients no endoscopy was performed after completing the
chemoradiation. Response evaluated with CT showed no complete
response or disease progression. In three patients (5.6%) a partial
response was observed.
Surgical results
One patient refused surgery after having completed the chemo-
radiotherapy. Endoscopy in this patient revealed a complete
response. After 12 months of follow-up, a local recurrence of the
oesophageal tumour was diagnosed, further workup also revealed
supraclavicular lymph nodes. He refused further treatment.
Thirteen months later he died from progressive disease. A
transhiatal oesophagectomy was performed in 46 of the 52
patients, and a transthoracic resection in 6 patients. The median
time between the completion of chemoradiotherapy and surgery
was 42 days (range 20–74 days). The in-hospital postoperative
mortality rate was 7.7% (CI 0–15%). Two patients died from
systemic complications due to anastomotic leakage, one patient
from a cerebral vascular accident one day after surgery, and one
from sepsis. Autopsy in the latter patient revealed a prostatitis as
the probable focus of the sepsis. Postoperative complications were
seen in 38 patients (73%). These complications were mainly
pulmonary (42%) or cardiac (13%) (Table 4). Besides the two
lethal anastomotic leaks, in 10 of the 48 (20.8%) patients surviving
postoperatively an anastomotic leak was seen. In five of them
(10.4%) the leakage was a radiological finding on routinely
performed contrast swallow postoperatively. In all patients the
clinical signs of the leak could be treated conservatively, but in two
patients (4.2%) the leak resulted in long-term nutritional support.
Twenty-two patients (45.8%) developed an anastomotic stricture
requiring endoscopic dilatation (range 1–27, median 7). Even-
tually, all patients were able to eat solid food.
Pathological results
In 13 patients no residual tumour in the resected oesophagus or
regional lymph nodes was found, corresponding to a pathological
complete response (pCR) rate of 25%. The pathological stages of
the other resection specimens were: pT1N0-1M0 in 12 patients
(23.1%), pT2N0-1M0 in 6 patients (11.5%), pT3N0-1M0 in 16
patients (30.8%), pT0-3N0-1M1A in 4 patients (7.7%), and
pT1N1M1B in 1 patient (1.9%). In 19 patients (36.5%) a regression
grade III, in 14 patients (26.9%) a regression grade II, and in 6
patients (11.5%) a histopathological regression grade I was seen. In
7 of the 18 patients (38.9%) with a pathological T3-stage only
scattered tumour cells were found in the resection specimen. A
radical resection with no evidence of tumour cells at the resection
margins (R0-resection) was obtained in all patients. The lymph
node dissection status showed a median of eight nodes (range 0–
30), derived from both regional and distant sites. In 13 patients
(25%) one or more positive lymph nodes were found (median 2,
range 1–6). The N-stage improved from N1, as assessed by EUS, to
N0 postoperatively in 19 patients (36.5%). In four patients (7.7%)
the N0-stage, as assessed by EUS, was changed towards a N1-stage
postoperatively.
Pulmonary toxicity
The post-treatment pulmonary function tests (measured 6 months
and 1 year after surgery) deteriorated significantly compared to the
pretreatment tests. The total lung capacity (TLC) decreased from
103% of the predicted value to 92% (P¼0.002). The vital capacity
(VC) declined from 105% of the predicted value to 96% (Po0.001).
The forced expiratory volume in 1s (FEV1) decreased from 94% of
the predicted value to 87% (Po0.0001). This decline in pulmonary
function tests did not lead to major clinical symptoms.
Survival
All 54 patients were included in the survival analysis. At the time of
evaluation (31 May 2005) the median follow-up time for all
patients was 23.5 months (range 0–52 months). The median
Table 3 Non-haematological toxicities
Grade
01234
(%) No. (%) No. (%) No. (%) No. (%) No. (%)
Nausea 15 (28.3) 35 (66) 3 (5.7) — —
Vomitus 36 (67.9) 15 (28.3) 2 (3.8) — —
Oesophagitis 11 (20.8) 23 (43.4) 15 (28.3) 4 (7.5) —
Lethargy 23 (43.4) 23 (43.4) 7 (13.2) — —
Skin toxicity 34 (64.2) 18 (34) 1 (1.9) — —
Data from 53 evaluable patients.
Table 4 Postoperative complications
Complication No. of patients
None 14
Pulmonary 22
a
Upper airway infection 9
Pneumonia 7
Chylothorax 3
Pulmonary embolism 2
Pleural effusion 2
Atelectasis 1
Pleural empyema 1
Acute respiratory distress syndrome 1
Cardiac 12
Atrial fibrillation 10
Decompensatio cordis 2
Asystole during intubation 1
Wound infection 5
Vocal cord paralysis 3
Other 9
Data from 52 evaluable patients.
aIn four patients two events.
Chemoradiation for patients with oesophageal cancer
E van Meerten et al
1392
British Journal of Cancer (2006) 94(10), 1389–1394 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sfollow-up time for surviving patients was 31 months (range 11–52
months). Nineteen of the 54 patients (35.2%) died: 13 due to
recurrent cancer, 5 during treatment (four postoperatively and one
sudden death) and 1 due to a ruptured aortic aneurysm. The
median survival time, however, has not yet been reached. The
estimated 1-, 2-, and 3-year survival rates were 82, 65, and 56%,
respectively. The Kaplan–Meier curve for overall survival is shown
in Figure 1. The survival of patients with a pCR was not better than
the survival of patients with no pCR. Recurrent disease after
surgery was found in 15 patients surviving postoperatively (15/48,
31.2%). Three of them were still alive at the time of analysis.
Recurrence was locoregional in seven patients. Distant metastases
were found in 14 patients. The patient who refused surgery died
from recurrent disease as well (see before). The Kaplan–Meier
curve for disease-free survival of the patients surviving post-
operatively is shown in Figure 1. The patient who died without
recurrence was censored at the time of death.
DISCUSSION
Preoperative chemoradiotherapy is nowadays widely used in the
treatment of patients with potentially resectable oesophageal
cancer. The concept that preoperative chemoradiotherapy may
lead to a better tumour control and therefore to a better overall
survival is appealing, as 29–43% incomplete resections are
performed when patients are treated with surgery alone or with
chemotherapy followed by surgery (Kelsen et al, 1998; Hulscher
et al, 2002; MRC, 2002). Many studies have reported that after
chemoradiotherapy in 10–28% of the patients no tumour cells are
found in the resection specimen (Apinop et al, 1994; Le Prise et al,
1994; Walsh et al, 1996; Bosset et al, 1997; Urba et al, 2001).
However, surprisingly few phase III studies have been reported in
which preoperative chemoradiotherapy followed by surgery was
compared with surgery alone. Meta-analyses of these trials showed
a small, if any, effect on survival (Kaklamanos et al, 2003; Urschel
and Vasan, 2003; Fiorica et al, 2004). In addition, the results of a
recently reported study were disappointing, showing no survival
benefit for those patients treated with preoperative chemo-
radiotherapy (Burmeister et al, 2005). In most studies, the
combination of 5-FU and cisplatin with radiotherapy has been
applied. In our study we used paclitaxel and carboplatin with
concurrent radiotherapy.
Our study showed that preoperative chemoradiotherapy with
weekly paclitaxel and carboplatin was well tolerated. All patients
completed the chemoradiotherapy as scheduled, without treatment
delay or dose reduction. The major non-haematological toxicity
was a grade 3 or 4 oesophagitis in 7.5% of the patients. Compared
to other studies with chemoradiotherapy in oesophageal cancer,
this incidence of grade 3 and 4 oesophagitis is low (Urba et al,
2001; Choi et al, 2004).
The postoperative mortality of this study (7.7%; 95% CI 0–15%)
was somewhat higher than the approximately 4% mortality rate
found in other trials performed at our institution (van Lanschot
et al,2 0 0 1 ;H u l s c h e ret al, 2002; Polee et al,2 0 0 3 ) ;h o w e v e r ,t h e
observed mortality rate still lies within the 95% confidence limits.
Postoperative morbidity consisted mainly of pulmonary complica-
tions. This high pulmonary complication rate is partly due to the
fact that we also scored minor pulmonary complications, such as
upper airway infections. Whether preoperative chemoradiotherapy
is responsible for a higher pulmonary complication rate cannot be
excluded. In a retrospective study of Avendano et al (2002)
preoperative chemoradiotherapy was associated with an increase
risk of pulmonary complications (i.e., duration of mechanical
ventilation). Whether the decline in pulmonary function tests (TLC,
VC, and FEV1) that we observed in our study was due to the
chemoradiotherapy is uncertain, as it has also been reported that the
TLC and the VC were significantly reduced after an oesophagectomy
without preoperative treatment (Crozier et al,1 9 9 2 ) .
During follow-up, 22 patients required dilatations because of an
anastomotic stricture. The dilatations resolved the dysphagia in all
patients, eventually all patients had an adequate food intake.
Neoadjuvant chemoradiotherapy has not been reported to be
associated with a higher stricture formation rate (Kelley et al, 2004).
In this study, the overall and disease-free survivals compare
favourably with those in other trials of preoperative chemoradia-
tion for oesophageal cancer. With a median follow-up of 23.5
months, the median survival time has not yet been reached.
However, such findings should be interpreted with caution,
because phase II studies always carry the risk of selection bias. A
complete (R0) resection was accomplished in all patients, using a
1mm cutoff point for circumferential resection margin and this
also compares favourably with other studies. The pathologically
complete response rate of 25% in our study is consistent with that
in other studies using preoperative chemoradiation. A major
histomorphological regression was seen in another 19 resected
specimens. Thus, in a total of 32 patients (61.5%) a major or
complete pathological response to preoperative chemoradiation
was found. Several studies have shown that a pCR and an R0-
resection are associated with a better prognosis (Hofstetter et al,
2002; Berger et al, 2005). Surprisingly, we were not able to
demonstrate a significant survival difference between patients who
had a pCR and those who did not have a pCR. As all operated
patients had an R0 resection, a possible adverse effect of an
incomplete resection on survival could not be assessed. The 100%
complete resection rate and high number of patients with a major
or complete pathological response might explain the lack of
survival benefit in patients who had a pCR.
In conclusion, this study shows that preoperative treatment with
weekly paclitaxel and carboplatin with concurrent radiotherapy is
well tolerated, with leucopaenia and oesophagitis being the most
common side effects. After chemoradiotherapy a high rate of
radical resections could be achieved and the overall survival looks
promising. A randomised phase III trial with this regimen followed
by surgery vs surgery alone is now ongoing, which has, up to now,
included more than 100 patients in the first year, to determine its
role in the treatment of resectable oesophageal carcinoma.
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